|
Building a learning network to accelerate improvement in pancreas cancer care and outcomes: Canopy Cancer Collective. |
|
|
Honoraria - Sirtex Medical |
Travel, Accommodations, Expenses - Varian Medical Systems; Varian Medical Systems |
Other Relationship - 1440 Foundation (Inst) |
|
|
Leadership - Gray Oncology Solutions |
Stock and Other Ownership Interests - Carevive Systems |
|
|
Employment - Sarah K Myers Consulting |
Stock and Other Ownership Interests - Sarah K Myers Consulting |
Consulting or Advisory Role - HIVE Networks |
|
|
No Relationships to Disclose |
|
|
Research Funding - Boston Scientific |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - PanTher Therapeutics |
Consulting or Advisory Role - Boston Scientific; Merck; Novocure; Syndax; Synthetic Biologics |
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Natera |
|
|
Honoraria - Bluestar Genomics; CPRIT; Novartis |
Consulting or Advisory Role - Abbvie; Astellas Pharma; BeiGene; Biomea Fusion; BioSapien; Bluestar Genomics; Bristol-Myers Squibb; Cend Therapeutics Inc.; Debiopharm Group; Geistlich Pharma; GlaxoSmithKline; Global Bio Access Fund; Ipsen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Merck; Mirati Therapeutics; Novartis Pharmaceuticals UK Ltd.; ONCOLYTICS; Steba Biotech; Swedish Orphan Biovitrum |
Research Funding - Bristol-Myers Squibb/Ono Pharmaceutical; Celgene; Halozyme; Pharmacyclics |
Travel, Accommodations, Expenses - Abbvie; BIOPHARM; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pharmacyclics; Pharmacyte Biotech |
|
|
Stock and Other Ownership Interests - Seagen (I) |
Honoraria - Advanced Accelerator Applications; Ipsen; Ipsen |
Consulting or Advisory Role - Hutchison MediPharma; Merck; Silenseed; Taiho Pharmaceutical |
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Merck (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche; Merck |
Other Relationship - CytomX Therapeutics; Taiho Oncology; TERUMO |
|
|
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen |
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst) |
Travel, Accommodations, Expenses - Abbvie; Halozyme |
|
|
Stock and Other Ownership Interests - Illumina |
Honoraria - Ipsen; Omni Health; Omni Health; Skysis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Trethera |
|
|
Employment - Voltmed; xCures |
Leadership - Voltmed; xCures |
Stock and Other Ownership Interests - Innavasc; Voltmed; xCures |
|
|
Stock and Other Ownership Interests - Hive Networks |
Consulting or Advisory Role - Hive Networks |